The effect of 5,5¢-diphenylhydantoin on thyroxine metabolism was examined in five normal volunteers. Intravenous injection of radiothyroxine was followed by a 10-12 day control and subsequent 9-14 day treatment periods. During oral administration of diphenylhydantoin, plasma thyroxine concentration decreased to about 80% of its pretreatment level and the plasma radiothyroxine disappearance rate increased a maximum of 20% over control estimates. These changes were a result of increases in both urinary and fecal excretion of radioisotope.
INTRODUCTION
The association of a decreased serum protein-bound iodine (PBI) in euthyroid patients receiving 5,5'-diphenylhydantoin (DPH) has been widely recognized since the initial report of Oppenheimer, Fisher, Nelson, and Jailer in 1961 (1) . As the effect of this drug on the PBI was identical whether given to hypothyroid patients receiving replacement therapy or to patients with normal thyroid function, its action was assumed to be extrathyroidal (1) . In subsequent studies, Wolff, Standaert, and Rall (2) and Oppenheimer and Tavernetti (3) demonstrated that DPH competed with thyroxine (T4) in vitro for binding sites on thyroxine-binding globulin (TBG) . Similar competition in vivo is thought to explain the low PBI during DPH treatment. The thyroxine kinetics in these subjects would presumably resemble those found in patients deficient in TBG binding ca- pacity. In these patients, the rapid turnover of a diminished thyroxine pool leads to the degradation of normal amounts of thyroxine and euthyroidism despite the low PBI (4, 5) .
These assumptions have not, to our knowledge, been verified by direct examination of thyroxine kinetics in subjects before and during DPH administration. This question has become more intriguing since the recent demonstration by Chin and Schussler that some patients receiving DPH have decreased free thyroxine concentrations (6) . If free thyroxine is rate-limiting in thyroxine degradation, a decrease would be expected to result in a decrease in thyroxine degradation and possibly to hypothyroidism. The following study was undertaken to examine the magnitude and time course of the effects of DPH on thyroxine metabolism and to correlate these effects with changes in the free thyroxine.
METHODS
The five normal volunteers used in this study were males, ages 35 through 61, hospitalized solely for the purpose of this study on the Clinical Research Unit of the University of Cincinnati Medical Center. There was no evidence of thyroid, renal, hepatic, or other disease known to affect thyroxine turnover in any volunteer by physical examination or laboratory study. Each received 100-200 mg of potassium iodide per day beginning several days before the intravenous administration of tracer T4-'I and throughout the study.
About 100-200 j/Ci of thyroxine-"3'I (Abbott Laboratories, North Chicago, Ill., specific activity 30-70 /Ci//ug) was administered using a calibrated syringe on day zero. The tracer for W. E., H. R., and C. S. had been dialyzed to remove contaminating "I-as suggested by Nicoloff and Dowling (7) . The residual "'I-was less than 0.2%o as determined on the day of injection by paper electrophoresis in glycine-acetate buffer, pH 8.6. The undialyzed tracer for D. S. and J. H. contained 2.4%o 131-and 2.1 o' "I-, respectively.
DPH (Dilantin, Parke, Davis & Co., Detroit, Mich.) was administered orally on the following various schedules: W. E. and H. R. received 6.7 mg/kg and 4.7 mg/kg, respectively, on days 12 through 26; J. G., 2.4 mg/kg on days 10 through 17 and 4.9 mg/kg on days 17 through 24; D. S., 7 .0 mg/kg on days 10 through 18; and C. S., 5.3 mg/kg on days 10 through 25. These dosages correspond to the usual therapeutic range of 300-400 mg/day. The subjects received no other medication during the period of study.
In subject D. S. the DPH was discontinued after 9 days because of the discovery of thrombocytopenia. He was subsequently found to have idiopathic thrombocytopenic purpura, which was thought to antedate this study.
Isotope measurements. After injection of T4-'uI, blood samples were collected in heparinized syringes at 5, 10-, 15- min, 3-hr, and 24-hr intervals throughout the control and treatment periods.
In the initial studies with W. E. and H. R., early morning ad libitum activity was allowed before venipuncture. We subsequently became aware of the increase in plasma thyroxine associated with the upright posture (8) , and all subsequent plasma samples were obtained after 6-8 hr bed rest.
The plasma thyroxine values for W. E. and H. R. were in the upper range of normal (vide infra).
Plasma T4-l"I concentration was estimated from the total radioactivity contained in 3-ml specimens counted in an automatic gamma well counter (Nuclear-Chicago Corp., Des Plaines, Ill.). Its activity was compared with suitably diluted fractions of the administered dose prepared at the time of injection. In vivo counting. An estimate of total body radioactivity was obtained from a profile scan of the patient in a whole body counter equipped with a 4 inch X 6 inch NaI (Ti) crystal. The patient was placed in a supine position and timed counts were obtained at nine standard locations 16 cm from the mid-coronal plane. The locations chosen were the head, neck, and shoulders, upper thorax, liver, mid-abdomen, pelvis, thigh, knees, and ankles. The placement of the crystal over these positions was constant from day to day. Each day the timed counts from each of the nine areas were totaled and this figure was used as an approximation of whole body activity. This was expressed as a percentage of the initial count obtained immediately after injection. These results were used to verify the accuracy of excretory collections. In all subjects there was good agreement between the profile scan results and the residual activity predicted from the urine and stool collections.
In addition, thyroid, liver, and heart radioactivity was also specifically monitored by either a dual 3 inch X 1 inch (thyroid, thigh) or 4 inch X 4 inch NaI (Ti) crystal. The hepatic and cardiac areas were located by percussion, and the desired crystal position was marked with indelible pencil. Only relative changes in organ radioactivity were obtained by this technique. Both profile scan and organ counts were obtained 5-7 days/wk.
Laboratory determinations. Plasma thyroxine levels were determined by the method of Murphy (9) with minor modifications. The yield of T4 in the initial ethanol extraction of plasma was 79.6 ±1.3% (mean SD) based on the extraction of T4-'3I (free of contaminating 131I-) from 21 different plasma samples at different times over the course of these studies. The presence of DPH had no effect on this extraction nor did it affect the subsequent displacement assay in amounts greatly in excess of those present in these samples. All reported thyroxine values were corrected for this incomplete yield. For these studies, duplicate 1-ml samples of plasma were extracted with ethanol and duplicate aliquots of each extraction were then assayed. Each sample group contained equal numbers of control and treatment samples to eliminate any error due to day to day variation in technique. A 1 ml sample from a single large serum pool was assayed with each determination for quality control. Over a 3 month period, the mean of 16 such determinations was 8.1 +0.1 /g/ 100 ml (mean +SE). The normal range of uncorrected values in our laboratory, 4-11 Ag/100 ml as thyroxine, is similar to values reported by others (9, 10) .
Free thyroxine was calculated from the product of the total plasma thyroxine concentration and the free thyroxine fraction (FTF). Radioactive thyroxine of high specific activity (labeled with '2I or "3'I) was obtained from Abbott Laboratories and dialyzed overnight against 4 liters of 0.15 M phosphate buffer after dilution (1: 1) with human serum. As was first noted by Schussler and Plager (11) , labeled T4 preparations contain dialysable contaminants, which may give artifactually high values for FTF. After dialysis, the inorganic I-concentration of the labeled T4 was consistently less than 0.1%v as determined by paper Diphenylhydantoin and Thyroxine Metabolism 1267 electrophoresis and remained less than 1% over the 7-10 days it was used.
The purified tracer was added to 8-10 ml of plasma at a concentration of 2-3 ,ug of T4 per 100 ml and incubated for 30 min in a shaking water bath at 370C in stoppered 25-ml Erlenmeyer flasks. These flasks and subsequent containers were gassed with 5%/95%-CO2/O2 to maintain the pH at 7.6-8.0. The serum was then transferred to bags made of Visking No. 20 (Visking Co., Division of Union Carbide Corp.) dialysis tubing prepared as described by Sterling and Brenner (12) . These bags were suspended in 50-ml polycarbonate test tubes (Ivan Sorvall) which were then placed in a Model CS International Centrifuge preheated to 370C by a water-heated coil of Tygon tubing (U. S. Stoneware Co., Akron, Ohio).
The tubes were centrifuged at speeds sufficient to produce about 0.6-0.8 ml of ultrafiltrate per hr at a temperature of 36-380C. It was determined that the first 0.1-0.2 ml of ultrafiltrate often contained a slightly higher (5-10%) concentration of T4-131I than the subsequent aliquot (or aliquots) of ultrafiltrate. Since this was observed for both plasma ultrafiltrate and in similar studies using T4-131I in protein-free 0.15 M P04 buffer (pH 7.4), it was thought to be artifactual. In the studies with phosphate buffer, the concentration of T4-"1I in the 2nd, 3rd, and 4th aliquots of ultrafiltrate was identical to that inside the bag. The initial 0.2-0.3 ml of ultrafiltrate was, therefore, discarded and the bags transferred to fresh polycarbonate tubes. Sequential studies in our laboratory have shown the FTF to be constant (after the first 0.2 ml) during removal of as much as 15%o of the initial serum volume. The quantity of ultrafiltrate was determined from the weight gained by the tube during the ultrafiltration process.
Quantitative transfer of the ultrafiltrate to plastic counting tubes was accomplished by two 1-ml washes of thyroxine (1 mg/ml) in 0.033 M NaOH as described by Sterling and Brenner (12). 2 ml of 0.15 M P04 buffer were added and the subsequent MgCl2 precipitation and washing procedure were carried out as described by the above authors. This technique results in a 95% recovery of T4, 86% recovery of T3, and less than 0.2% coprecipitation of labeled I-as determined by addition of known quantities of these materials to plasma ultrafiltrate. The same methods were followed for the determination of FT3F except that the serum was enriched with 2 m~ug/ml of "'3I-labeled triiodothyronine (Abbott Laboratories). All FT3 fractions were corrected for the 86% yield in the MgCl2 precipitation step.
In 14 successive analyses of a single serum pool from hospital patients, a value for FTF of 0.035 +0.002%, (mean +SD) was obtained. In 25 separate determinations in normal subjects, the FTF was 0.026 +0.003% (mean +-SD). The absolute free thyroxine (FT4) in these subjects was 2.8 ±0.3 m/Lg/100 ml (mean +SD) as thyroxine. By the same methods, the FT3F in 12 separate determinations in a single normal serum pool was 0.36 +0.02%o (mean ±+SD).
In determining FTF and FTYF in this study, all determinations on a given volunteer were performed in the same week with the same labeled thyroxine or triiodothyronine. Each run of 2-3 treatment samples contained at least one control sample since on one occasion prolonged predialysis had not removed all dialyzable contaminants. SuffiZient counts were collected to obtain less than 2%o counting error.
The distribution of small amounts (2-3 /Lg/100 ml) of T4-1I on the serum thyroxine-binding proteins was performed by the reverse-flow paper electrophoresis method of Elzinga, Carr, and Beierwaltes (13) . Thyroxine-binding globulin capacity was determined using the same techniques with unlabeled thyroxine added in a concentration of 75 /g/ 100 ml. Thyroxine-binding prealbumin (TBPA) capacity was determined by the method of Oppenheimer, Martinez, and Bernstein with concentrations of 600 ug/100 ml of unlabeled thyroxine (14) . All enrichment of plasma for a given volunteer was carried out with the same stock solutions of labeled and unlabeled thyroxine and the specimens of each subject were run simultaneously in duplicate with a quality control sample. The distribution of the labeled thyroxine was determined by planimetry after scanning with a Packard Model 7201 radiochromatogram scanner. The DPH levels were kindly measured by Dr. Emile E. Werk of the Metabolism Division of the University of Cincinnati. The method used requires extraction of diphenylhydantoin into chloroform, followed by thin-layer chromatography and ultraviolet absorption spectroscopy. A tracer amount of DPH-'4C is added to the inital sample to permit correction for losses of DPH during the extraction.
Analysis of kinetic data. Multicompartmental models were developed to permit the simultaneous analysis of T4-13'I tracer studies and the observed changes in total plasma T4 and DPH concentrations. Linear first-order differential equations were used to describe the transfer of material between model compartments such that
where fi(t) is the amount of material in model or functiongenerator compartment i at time t and Xij is the fractional rate of transfer of material from compartment j to compartment i. Certain parameters and variables for the single-compartment model were assigned special symbols to conform to the usage of previous investigators (15) . They are the following: T4, the quantity of total thyroxine in its volume of extrathyroidal distribution; [T4], the plasma concentration of total thyroxine; XOT, the fractional turnover of total extrathyroidal thyroxine; Xos, the fractional turnover of total thyroxine due to fecal elimination; Xou, the fractional turnover of total thyroxine due to peripheral deiodination, as indicated by urinary excretion of 111I-; VT, the extrathyroidal distribution volume of thyroxine; ps, the net quantity of thyroxine entering VT 
In the schematic representation of the kinetic models (Figs. 1 and 4), the circles represent the compartments of T4-'13I distribution and excretion. The arrows indicate assigned routes of transfer of T4-'I between these compartments. Triangles cutting into compartments represent observations that are directly proportional to the contents of the compartment. Other observations consisting of a linear combination of contributions from compartments are represented by free-standing triangles called summers by Berman, Weiss, and Shahn (16) . For example, both plasma and interstitial fluid contribute to the activity that is shown as total body T4-'3I in Fig. 4 .
The interaction between DPH and plasma [T4] is included in the models by means of the squares shown in the schematic drawings. An operational relationship between the plasma concentration of DPH and [T41 is indicated by the interconnections between these compartments. As a result of preliminary testing, the function generated as f7 was used to represent the change in T4-1311 elimination that was observed during DPH administration. During the pretreatment period, f7 was assigned a value of 1, so that in this period, XOU/f7 and Xos/f7 represented the control values of Xou (17) . The computer automatically adjusted the initial estimates of the parameter values by an iterative process until a least squares fit to the experimental data was obtained. The values for the model parameters were used to generate theoretical curves based on the models, and these curves were then compared to the experimental data. Computations were repeated until no systematic deviation of the calculated curves from the experimental data was apparent and until further successive iterations improved the sum of the squared deviations by less than 2%.
The data that were simultaneously analyzed included plasma, daily urine, cumulative stool, whole body T4-139I activity (in one case), plasma total thyroxine, and DPH concentrations. When the single-compartment model was used, the criteria of Ingbar and Freinkel (18) were adapted for computer use to judge completeness of mixing of the injected radiothyroxine. Counting data obtained before complete mixing were not included in the kinetic analysis. Remaining data were given equal weight in the curve-fitting process save for urinary collections that were incomplete as determined from the 24 hr creatinine excretion. These data were not included in the computer analysis, but are shown as circled points in Figs. 2 and 3 . The validity of this approach was tested in one case by including all mixing phase plasma, urine and fecal values, and incorporating profile scan data to estimate the parameters of a three-compartment model. The three-compartment model was chosen since it was the simplest one which could satisfy the distribution kinetics.
Daily urine T4-1'31I excretion data were used in preference to cumulative urine T4-1311 excretion data because the latter are greatly affected by any losses of urine. (Fig.  6) . The probability of chance differences between these calculated slopes and 0 or -1 was determined by a standard two-tailed t test (19) .
RESULTS
Kinetic analyses. Theoretical curves were fitted to the experimental data according to the single-compartment model depicted in Fig. 1 . The radiothyroxine kinetic data of one subject (H. R.) could not be used because of errors in the preparation of standards. In Figs. 2 and 3 , the results of the analyses of W. E. and C. S. are depicted. The parameter estimates calculated from the single-compartment analyses for these and the other two subjects are presented in Table I . It can be seen that the observed data are generally within +5% of the theoretical curves and that there are no systematic deviations of the expected from the actual data.
The thyroxine distribution volume, VT, was calculated assuming a uniform distribution of the administered T4-'11I within a single-compartment. This volume averaged 15% of body weight. The fractional turnover rate of thyroxine, XOT, is given for the control period. This parameter is the sum of the fractional urine and stool elimination rates with urinary excretion accounting for an average of 81 % of total T4-131I elimination.
Both [T4] and net thyroxine excretion, po, are expressed in Table I Although fecal TA-XI is shown arising from the plasma pool, the length and variability of the fecal excretory lag time make this a somewhat arbitrary assignment. Whole-body radioactivity was estimated independently from profile scans. Although the nonlinearity of the 'A. J. Atkinson, Jr. Unpublished observations. whole body curve shown in Fig. 5 indicates a larger contribution from the slowly equilibrating interstitial fluid compartment than would be expected if these were true whole-body counts, the profile scan does contain contributions from all three compartments in a fixed proportion. The results of this kinetic analysis suggest that there is no major shift of To to the "slow" compartment during DPH therapy. In addition, serial collimated detector counts over the thigh, liver, and heart of each subject (not shown) demonstrated no change in the relative distribution of radioactivity during the DPH treatment period.
Free thyroxine. Free triiodo'hyronine. Since triiodothyronine (T3) is also bound to TBG, it might be expected that DPH would increase the free Ts fraction (FTsF) in vitro. A mean increase of 10 ±2% (mean +SD) in FT3F was observed in five normal serum pools at an added DPH concentration of 15 /Ag/ml. The FTsF was measured during DPH administration in C. S.; the mean FT3F in the control period was 0.37% compared with 0.38% during DPH treatment. Since total Ts levels are not available in this subject, absolute free Ts concentration cannot be determined. Nevertheless, the absence of a change in the FT3F in vivo is similar to the lack of DPH effect on FTF.
Thyroxine-binding protein. Frequent examination of the plasma TBG and TBPA capacities did not show significant alterations during DPH administration (Table III). Furthermore, we were unable to demonstrate significant DPH-induced alterations in the distribution of small quantities (2-3 b'g/100 ml) of T4-lJI among the binding proteins.
DISCUSS ION
The estimates of the parameters of thyroxine metabolism obtained using the single-compartment model are in general agreement with those obtained by previous investigators. The volume of distribution of thyroxine, 15% of body weight, is identical to that reported by Ingbar and Freinkel (20) and slightly greater than the 13.4% reported by Rall, Robbins, and Lewallen in their review of the literature (15) . Control estimates for XOT and po are also similar to those described previously, and the percentage of injected T4-l"'I excreted in the stool (16-22%) is similar to the values observed by Van Middlesworth (21) .
Previous investigators have noted no alterations in 24 hr thyroidal "3'I uptake, thyroidal iodide clearance, cholesterol, or basal metabolic rate (BMR) in subjects receiving DPH (1) . The suggestion that thyroxine secretion was unchanged during DPH therapy is in keeping with these reports as is the normal absolute rate of thyroxine degradation in the two subjects whose plasma thyroxine levels reached a new steady state.
Displacement of thyroxine from TBG by DPH has been considered the cause of the low PBI of patients receiving DPH therapy. The correlation between the observed decrease in plasma radiothyroxine and the observed increase in urinary and fecal excretion indicates that DPH treatment caused increased thyroxine elimina.-tion and is in agreement with this hypothesis. No significant redistribution of thyroxine during DPH therapy could be detected by the multicompartmental analysis of the data obtained from D. S. This is especially important since it eliminates the possibility of a shift of thyroxine from the fast compartments, adequately sampled as plasma, to the slowly equilibrating one. While we were unable to demonstrate significant shifts of thyroxine between these three compartments, intracompartmental redistribution might occur. The interstitial fluid compartments are defined by their kinetic behavior and may be anatomically heterogeneous. It is unlikely that any of the compartments of our model represents intracellular thyroxine. First of all, the slow interstitial fluid compartment is too small to account for the interstitial fluid Diphenylhydantoin and Thyroxine Metabolism space by itself; and secondly, intracellular deiodination parallels thyroxine distribution within the fast rather than the slow compartment. Nevertheless, a certain amount of thyroxine must presumably be present within cells before deiodination. However, the fraction of the total hormone bound to extracellular protein (and hence restricted to the extracellular fluid space) is so large that the analysis of the experimental data lacks the resolving power to define an intracellular thyroxine compartment. We were, therefore, unable to demonstrate significant intracellular sequestration of thyroxine during DPH administration such as described during acute infusion studies by Oppenheimer, Bernstein, and Hasen (22) . The data indicate that elimination of thyroxine, rather than redistribution, is the major fate of the thyroxine lost from the plasma during more prolonged DPH therapy.
When DPH was added to plasma in vitro we found that FT increased by 10% at DPH concentrations of 10 Ag/ml and 22% at concentrations of 20 /g/ml similar to the previous report of Chin and Schussler (6) . Thus we anticipated that the administration of DPH to our subjects would result in an initial rise in FT4 followed by a return to pretreatment levels as a new euthyroid steady state was established. On the contrary, we encountered a gradual fall in FT after DPH administration that was similar in magnitude to the decrease of 13% reported after 2-3 wk of DPH treatment by the above investigators (6 this ratio by Oppenheimer and Tavernetti using as in vitro method was 18,000 (3). However, in our subjects the calculated ratio averaged 2300, indicating that DPH was almost 10 times more effective in lowering plasma thyroxine than would have been expected on the basis of the in vitro study. These observations do not explain the presence of a decreased absolute FT4 during DPH treatment. It has been postulated from repeated observations that FT4 is the only portion of this hormone available for cellular uptake (15) . Free thyroxine is also thought to control the release of thyrotropin (TSH) through its feedback regulation of TSH-releasing factor (TRF). A low FT4 concentration, by decreasing thyroxine uptake in the hypothalamus, would allow secretion of TRF which would mean an increase in TSH and thyroid gland stimulation. In two of these subjects, plasma FT4 concentrations decreased while absolute thyroxine degradation was unchanged. This indicates that the peripheral clearance of free thyroxine has increased.
The mechanism by which DPH increases the peripheral clearance of FT4 is not known. Since administration of this drug to mice causes increases in the smooth endoplasmic reticulum of the liver, DPH could conceivably increase the hepatic clearance of thyroxine through enzyme induction (23) . Other agents which induce microsomal enzymes, such as phenobarbital, have been associated with increased rates of thyroxine metabolism in rats though the effect on free thyroxine clearance was not examined (24) . The studies of Mendoza, Flock, Owen, and Paris have shown that pretreatment of rats with 60-80 mg/kg of DPH (more than 10 times the amount used in these studies) increases the excretion of thyroxine glucuronide in bile by about 30% (25). However, the increase in free thyroxine clearance observed in our subjects cannot be attributed entirely to an increase in the biliary excretion of thyroxine since the kinetic studies indicate that peripheral deiodination increases to an equal extent. Furthermore, in order to explain the lack of TSH release and the persistent decrease in FT4, the hypothalamus would presumably be required to participate in this increased clearance of thyroxine.
It is premature to conclude that the observed increase in free thyroxine clearance is mediated by DPH itself. Conceivably, it might reflect an increased cellular uptake of thyroxine due to decreased availability of TBG. If this were true, some similarities might be expected between DPH-treated patients and those with a congenital deficiency in TBG-binding capacity. These patients do resemble our subjects in having both accelerated urinary and fecal radiothyroxine clearances, a decreased 1276 P. R. Larsen (4, 5) . Unfortunately, FT4 measurements using predialyzed thyroxine tracer have not been generally employed in these subjects. A subnormal value of 0.9 mjtg/100 ml can be calculated for one such patient from data in a recent study reported by Woeber and Ingbar (26) . Additional information is needed to determine whether or not this low value is typical of this condition and, if so, whether thyroxine degradation rates are nevertheless maintained at normal levels. Regardless of the mechanism by which DPH therapy increases free thyroxine clearance, it appears that a low plasma free thyroxine does not imply hypothyroidism in 
